Stock Watch: J&J And Novartis Fire Opening Salvos Of Earnings Season
Reports Differ In Outlook And Reception
Executive Summary
J&J’s bullish outlook for 2021, robust fourth quarter and frequent guidance revisions in uncertain times contrasted with Novartis’s reticence.
You may also be interested in...
Stock Watch: Third-Quarter Earnings Season – The New Endemic Normal
With the latest Delta variant wave in the rear-view mirror, vaccine and antiviral sales, and their impact on full-year guidance, are likely to remain the big swing factors in third-quarter earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.